Requirement 1: a method for the treatment of melanoma patients with B-Raf mutations, especially B-Raf V600 mutations, including: (a) obtaining and analyzing tumor samples of patients to determine their tumors. a. Gene modification of a group of genes including BRAF, craf, CCND1, CDK4, HER2, IGF-1R, CMET, FGFR1, FGFR2, FGFR3, EFR, map2k1, map2k2, NRAS, KRAS HRAS, PTEN, plk3ca and p16； (b) drug combination therapy including B-Raf inhibitor and the second inhibitor；The second inhibitor is selected according to the gene changes found in the tumor samples. In the case of gene changes in BRAF, craf, map2k1, mapk2, NRAS, KRAS HRAS or EGR in the tumor samples, the second inhibitor is MEK 1 / 2 inhibitor. O (II) the second inhibitor is CDK4 inhibitor. When the tumor sample has gene change in CCND1, CDK4 or p16, or (III) when the tumor sample has gene change in HER2, IGF-1R, PTEN or PIK3CA, the second inhibitor is PI3 quinase inhibitor,The second inhibitor of O (IV) is the c-met thyroid receptor inhibitor. When there is gene change in CMET in tumor samples, and (V) when there is gene change in FGFR1, FGFR2 or FGFR3 in tumor samples, the second inhibitor is FGFR quintasa inhibitor. Claim 2: a method of claim 1, wherein the B-Raf inhibitor is a formulated compound (1). Requirement 13: select the diagnosis method of combination of the second inhibitor and B-Raf inhibitor, and analyze the tumor samples in the gene panel of B-Raf, c-raf, CCND1, CDK4, HER2, IGF-1R, CMET and FGFR1 to determine the gene change,FGFR2, FGFR3, EFR, map2k1, mapzk2, NRAS, KRAS HRAS, PTEN, plk3ca and p16. Requirement 14: diagnostic package for detecting gene change in B-Raf, c-raf, CCND1, CDK4, herm and other gene groups；IGF-1R, CMET, FGFR1, FGFR2, FGFR3, EGFR, map2k1, map2k2, NRAS, KRAS HRAS, PTEN, PIK3CA and p16.Reivindicación 1: Un método para tratar un paciente que sufre de una enfermedad proliferativa caracterizada por una mutación en B-Raf, particularmente una mutación V600 en B-Raf, muy particular
